Therapeutics News and Research

RSS

NIAID awards ATCC multimillion dollar MID-BRR contract

ATCC, the premier biological materials resource, services, and standards organization, has been awarded the National Institute of Allergy and Infectious Diseases, Microbiology and Infectious Diseases Biological Resource Repository ("MID-BRR") contract, ATCC announced today. The current value of the contract is $14,615,598 with the ultimate value of $115,733,409 over 7 years with an annual renewal.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Invida Group, Amdipharm partner to promote proprietary products in key Asian markets

Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into an agreement with Amdipharm for the licensing and commercialization of its proprietary products throughout Asia. Under this agreement, Invida will leverage its full suite of capabilities to bring Amdipharm's products to market, from regulatory approval and licensing, through packaging and supply chain optimization, to commercialization, sales, and marketing.

14 Jul 2010

Silence Therapeutics extends ongoing research, development collaboration with AstraZeneca

Silence Therapeutics plc is pleased to announce a one-year extension of its ongoing research and development collaboration with AstraZeneca. Under the terms of the agreement, which has progressed well since being signed in July 2007, Silence and AstraZeneca are jointly collaborating in the identification and optimization of five novel siRNA therapeutic molecules addressing respiratory and oncology indications.

14 Jul 2010

CTI signs agreement with NerPharMa for long-term manufacture of pixantrone

Cell Therapeutics today announced that it has signed a manufacturing agreement with NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences S.r.l. for CTI's drug candidate pixantrone.

14 Jul 2010

RXi Pharmaceuticals receives SBIR grant to further develop novel RNAi therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded an Advanced Technology Small Business Innovation Research grant by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

13 Jul 2010

Anika to defend patent infringement lawsuit for MONOVISC product

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair, based on hyaluronic acid technology, announced today that they had been served with a complaint alleging patent infringement with respect to the MONOVISC product by Genzyme Corporation.

13 Jul 2010

BioMimetic announces common stock public offering

BioMimetic Therapeutics, Inc. announced today a public offering of 5,000,000 shares of its common stock. BioMimetic has granted the underwriters an option to purchase up to an additional 15% of shares of common stock to cover over-allotments. BioMimetic expects to use the net proceeds of the offering for development and commercialization of its product pipeline and general corporate purposes.

13 Jul 2010

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

12 Jul 2010

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

AmpliMed Corporation, a cancer therapeutics company, today announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas.

12 Jul 2010

MRC Technology, Genentech sign licensing agreement

MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease.

12 Jul 2010

Researchers demonstrate that MSNs can effectively suppress tumors in mice

The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.

12 Jul 2010

InVasc Therapeutics announces initial closing of $3,150,000 in first institutional financing

InVasc Therapeutics, Inc. today has had an initial closing of $3,150,000 in its first institutional financing. The investment was led by Trois I Investments Industriels Internationaux S.A., headquartered in Luxembourg.

9 Jul 2010

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.

9 Jul 2010

Massage improves psychological, physiological state of patients with tension headache

Researchers at the University of Granada -in collaboration with the Clinical Hospital San Cecilio and the University Rey Juan Carlos- have proven that the psychological and physiological state of patients with tension headache improves within 24 hours after receiving a 30-minute massage.

9 Jul 2010

iPierian announces closing of $22M Series B equity financing round

iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.

9 Jul 2010

Calithera Biosciences completes Series A financing totaling $40M

Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.

8 Jul 2010

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza™ that support its use in a hospital setting.

8 Jul 2010

Study: 30-minute massage improves psychological, physiological state of patients with tension headache

8 Jul 2010

USF granted patent for cell transplantation procedure

The University of South Florida's Department of Neurosurgery and Brain Repair has been granted a patent for a cell transplantation procedure combining human umbilical cord blood cells and a sugar-alcohol compound called "mannitol" that may make a big difference in treating life-threatening neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke, among others.

8 Jul 2010

Therapeutics News and Research

NIAID awards ATCC multimillion dollar MID-BRR contract

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Invida Group, Amdipharm partner to promote proprietary products in key Asian markets

Silence Therapeutics extends ongoing research, development collaboration with AstraZeneca

CTI signs agreement with NerPharMa for long-term manufacture of pixantrone

RXi Pharmaceuticals receives SBIR grant to further develop novel RNAi therapeutics

Anika to defend patent infringement lawsuit for MONOVISC product

BioMimetic announces common stock public offering

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

MRC Technology, Genentech sign licensing agreement

Researchers demonstrate that MSNs can effectively suppress tumors in mice

InVasc Therapeutics announces initial closing of $3,150,000 in first institutional financing

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Massage improves psychological, physiological state of patients with tension headache

iPierian announces closing of $22M Series B equity financing round

Calithera Biosciences completes Series A financing totaling $40M

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Study: 30-minute massage improves psychological, physiological state of patients with tension headache

USF granted patent for cell transplantation procedure

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News